Get notified when CYCN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — Cyclerion's financial statements and auditor's report include substantial doubt about its ability to continue as a going concern, and management states cash will not be sufficient to fund operations until the merger completes.
  • Sole Employee (new) — The company has only one employee, creating extreme key-person risk.
  • Delisted (new) — The company previously faced delisting and could face it again if the stock price falls below $1.00.
  • Shell Company (new) — The combined company will be treated as a former shell company, limiting its ability to use Form S-3 for 12 months and restricting resales under Rule 144 for one year.
  • Dilution (new) — Cyclerion shareholders will be diluted to about 1.1% ownership after the merger, while Korsana securityholders will own about 98.9%.
NASDAQ: CYCN Cyclerion Therapeutics, Inc. 424B3

Cyclerion to merge with Korsana in reverse merger; Korsana holders to own 98.9% of combined company

Filed July 24, 2026 · ~2 min read

Key Changes

  • high

    Cyclerion and Korsana propose a merger where Korsana becomes a wholly owned subsidiary and Cyclerion renames to Korsana Biosciences, Inc.

    The Offering verify on EDGAR →
  • high

    Immediately after the merger, Cyclerion securityholders are expected to own approximately 1.1% of the combined company, while former Korsana securityholders own approximately 98.9%.

    Prospectus Summary verify on EDGAR →
  • high

    Korsana has secured a $380 million pre-closing financing from institutional and accredited investors, contingent on the merger closing.

    Prospectus Summary verify on EDGAR →

5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.

Partner

Trade CYCN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify